Characteristic | All (n = 590) | SRb (n = 168) | SRinsDTc (n = 111) | SRnoDTd (n = 26) | noSRe (n = 121) | noLAf (n = 164) |
---|---|---|---|---|---|---|
Year of validity | ||||||
2009 | 41 (6.9%) | 4 (3.6%) | 2 (7.7%) | 7 (5.8%) | 16 (9.8%) | 12 (7.1%) |
2010 | 44 (7.5%) | 6 (5.4%) | 4 (15.4%) | 9 (7.4%) | 13 (7.9%) | 12 (7.1%) |
2011 | 69 (11.7%) | 17 (15.3%) | 3 (11.5%) | 8 (6.6%) | 26 (15.8%) | 15 (8.9%) |
2012 | 95 (16.1%) | 22 (19.8%) | 6 (23.1%) | 22 (18.2%) | 16 (9.8%) | 29 (17.3%) |
2013 | 115 (19.5%) | 27 (24.3%) | 4 (15.4%) | 28 (23.1%) | 22 (13.4%) | 34 (20.3%) |
2014 | 141 (23.9%) | 20 (18.1%) | 4 (15.4%) | 30 (24.8%) | 40 (24.4%) | 47 (28.0%) |
2015a | 85 (14.4%) | 15 (13.5%) | 3 (11.5%) | 17 (14.1%) | 31 (18.9%) | 19 (11.3%) |
Scope | ||||||
Broad | 244 (41.4%) | 29 (26.1%) | 15 (57.7%) | 74 (61.2%) | 77 (47.0%) | 49 (29.2%) |
Focused | 346 (58.6%) | 82 (73.9%) | 11 (42.3%) | 47 (38.8%) | 87 (53.0%) | 119 (70.8%) |
Producer | ||||||
Government Agency | 108 (18.3%) | 10 (9.0%) | 0 | 3 (2.5%) | 6 (3.7%) | 89 (53.0%) |
Independent Expert Panel | 80 (13.5%) | 11 (9.9%) | 5 (19.2%) | 27 (22.3%) | 25 (15.2%) | 12 (7.0%) |
Professional / Specialist Society | 378 (64.1%) | 83 (74.8%) | 16 (61.6%) | 88 (72.7%) | 125 (76.2%) | 66 (39.3%) |
Other | 24 (4.1%) | 7 (6.3%) | 5 (19.2%) | 3 (2.5%) | 8 (4.9%) | 1 (0.6%) |
Continent | ||||||
Asia | 52 (8.8%) | 10 (9.0%) | 6 (23.1%) | 7 (5.8%) | 24 (14.6%) | 5 (2.9%) |
Oceania | 14 (2.4%) | 3 (2.7%) | 1 (3.8%) | 3 (2.5%) | 2 (1.2%) | 5 (2.9%) |
Europe | 222 (37.6%) | 18 (16.2%) | 10 (38.5%) | 78 (64.4%) | 76 (46.3%) | 40 (23.8%) |
North America | 247 (41.9%) | 71 (64.0%) | 3 (11.5%) | 19 (15.7%) | 45 (27.5%) | 109 (64.9%) |
South America | 7 (1.2%) | 2 (1.8%) | 0 | 3 (2.5%) | 1 (0.6%) | 1 (0.6%) |
International | 48 (8.1%) | 7 (6.3%) | 6 (23.1%) | 11 (9.1%) | 16 (9.8%) | 8 (4.9%) |
Neoplasm | ||||||
Anal cancer | 9 (1.5%) | 3 (2.7%) | 0 | 1 (0.8%) | 2 (1.2%) | 3 (1.8%) |
Biliary cancer | 12 (2.0%) | 3 (2.7%) | 6 (23.1%) | 2 (1.7%) | 1 (0.6%) | 0 |
Bladder cancer | 27 (4.6%) | 9 (8.1%) | 2 (7.8%) | 4 (3.3%) | 5 (3.1%) | 7 (4.2%) |
Breast cancer | 45 (7.6%) | 8 (7.2%) | 3 (11.5%) | 5 (4.1%) | 14 (8.5%) | 15 (8.9%) |
Cervical cancer | 18 (3.0%) | 4 (3.6%) | 2 (7.8%) | 3 (2.5%) | 4 (2.4%) | 5 (3.0%) |
Colorectal cancer | 52 (8.8%) | 12 (10.8%) | 1 (3.8%) | 12 (9.9%) | 14 (8.5%) | 13 (7.7%) |
Endometrial cancer | 17 (2.9%) | 5 (4.5%) | 0 | 3 (2.5%) | 3 (1.8%) | 6 (3.5%) |
Esophageal cancer | 15 (2.5%) | 2 (1.8%) | 0 | 4 (3.3%) | 3 (1.8%) | 6 (3.5%) |
Gastric cancer | 18 (3.1%) | 2 (1.8%) | 0 | 4 (3.3%) | 9 (5.5%) | 3 (1.8%) |
Germ cell tumor | 3 (0.5%) | 0 | 0 | 1 (0.8%) | 1 (0.6%) | 1 (0.6%) |
Head and neck cancer | 16 (2.7%) | 0 | 1 (3.8%) | 5 (4.1%) | 7 (4.3%) | 3 (1.8%) |
Hepatocellular carcinoma | 29 (4.9%) | 4 (3.6%) | 2 (7.8%) | 7 (5.8%) | 10 (6.1%) | 6 (3.5%) |
Incidentaloma | 5 (0.9%) | 2 (1.8%) | 0 | 0 | 2 (1.2%) | 1 (0.6%) |
Lung cancer | 55 (9.3%) | 10 (9.1%) | 1 (3.8%) | 7 (5.8%) | 12 (7.3%) | 25 (14.9%) |
Melanoma | 20 (3.4%) | 0 | 1 (3.8%) | 4 (3.3%) | 8 (4.9%) | 7 (4.2%) |
Mesothelioma | 8 (1.4%) | 0 | 1 (3.8%) | 1 (0.8%) | 3 (1.8%) | 3 (1.8%) |
Metastatic ab initio | 4 (0.7%) | 4 (3.6%) | 0 | 0 | 0 | 0 |
NETs | 23 (3.9%) | 3 (2.7%) | 1 (3.8%) | 9 (7.5%) | 7 (4.3%) | 3 (1.8%) |
Ovarian cancer | 28 (4.8%) | 4 (3.6%) | 1 (3.8%) | 7 (5.8%) | 7 (4.3%) | 9 (5.4%) |
Pancreatic cancer | 17 (2.9%) | 2 (1.8%) | 1 (3.8%) | 3 (2.5%) | 6 (3.7%) | 5 (3.0%) |
Penile cancer | 5 (0.9%) | 2 (1.8%) | 0 | 1 (0.8%) | 1 (0.6%) | 1 (0.6%) |
Pleural disease | 2 (0.3%) | 0 | 0 | 0 | 0 | 2 (1.2%) |
Prostatic cancer | 68 (11.5%) | 15 (13.5%) | 2 (7.8%) | 12 (9.9%) | 18 (11.0%) | 21 (12.5%) |
Renal cancer | 23 (3.9%) | 5 (4.5%) | 0 | 6 (5.0%) | 6 (3.7%) | 6 (3.5%) |
Testicular cancer | 14 (2.4%) | 1 (0.9%) | 1 (3.8%) | 5 (4.1%) | 3 (1.8%) | 4 (2.4%) |
Thyroid cancer | 25 (4.2%) | 7 (6.3%) | 0 | 6 (5.0%) | 5 (3.1%) | 7 (4.2%) |
Unknown primary site | 4 (0.7%) | 0 | 0 | 1 (0.8%) | 2 (1.2%) | 1 (0.6%) |
Multiple cancer | 25 (4.2%) | 4 (3.6%) | 0 | 8 (6.6%) | 11 (6.7%) | 2 (1.2%) |
Other | 3 (0.5%) | 0 | 0 | 0 | 0 | 3 (1.8%) |